Hematopoietic stem cell transplantation in the treatment of 131I secondary bone marrow hematopoietic failure: one case report
10.3760/cma.j.cn421203-20230711-00022
- VernacularTitle:造血干细胞移植术治疗 131I继发骨髓造血衰竭1例
- Author:
Jing WANG
1
;
Fang ZHOU
Author Information
1. 解放军联勤保障部队第九六〇医院血液病科，济南 250031
- Keywords:
Hematopoietic stem cell transplantation;
131I treatment;
Secondary bone marrow hematopoietic failure
- From:
Chinese Journal of Organ Transplantation
2024;45(6):412-414
- CountryChina
- Language:Chinese
-
Abstract:
To summarize the experience of diagnosing and treating severe myelosuppression secondary to 131I dosing for thyroid cancer. After 131I treatment, this patient developed pancytopenia. Bone marrow morphology and biopsy indicated a lower proliferation of bone marrow cells and flow cytometry showed no presence of primitive cells. Thus a diagnosis of secondary myelopoietic failure was made. Despite initial treatments of danazol, cyclosporine and mesenchymal stem cells, disease continued to progress. Subsequently, unrelated donor hematopoietic stem cell transplantation was performed with a myeloablative preconditioning regimen. There was long-term symptom-free survival. Allogeneic hematopoietic stem cell transplantation is both effective and safe for bone marrow hematopoietic failure after 131I therapy. However, large-scale clinical studies are required for confirming these findings.
